Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02410694
Other study ID # AGMT_MM-1
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date April 2015
Est. completion date May 2, 2019

Study information

Verified date December 2019
Source Arbeitsgemeinschaft medikamentoese Tumortherapie
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Overview of Study Design:

This is an open phase II, single-arm, multi-center study to evaluate progression free survival in patients receiving ixazomib in combination with thalidomide and dexamethasone (ITD) followed by an ixazomib maintenance phase of a maximum period of 12 months.

The patient population will consist of adult male and female patients with multiple myeloma (MM) with relapsed and/or refractory disease after at least one prior treatment line.

In case of enrollment patients will receive ixazomib 4.0mg at days 1, 8, 15, thalidomide 100mg at days 1 to 28 (50mg in patients aged ≥75 years), and dexamethasone 40mg (20mg in patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle. The proposed number of cycles is 8. Treatment will be discontinued in case of progressive disease or in case of no response after 4 cycles (≤ SD after 4 cycles). After discontinuation of therapy an end of treatment visit (EOT) will be performed within 14 days after the last dose of the last combination treatment cycle.

After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be administered to patients with ≥ MR for a maximum period of 12 months. Patients who completed less than 8 cycles of ITD treatment do not qualify for maintenance phase.

Follow-up visits will be performed in 3-monthly intervals until the last patient on ixazomib maintenance therapy has concluded or discontinued the maintenance phase.

A safety analysis will be conducted after enrollment of the first 6 patients and completion of at least two cycles in every patient.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date May 2, 2019
Est. primary completion date March 28, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male or female patients 18 yrs or older.

2. Voluntary written consent

3. Patients in need of therapy with a diagnosis of relapsed or refractory multiple myeloma who had at least one prior treatment line

4. Patients must have measurable disease defined by at least 1 of the following criteria:

- Serum M-protein = 10g/l

- Urine M-protein = 200mg/24h

- Serum free light chain assay: involved serum light chain = 10mg/dl provided that free light chain ration is abnormal

5. Life expectancy > 3 months

6. ECOG (Eastern Cooperative Oncology Group) = 2

7. • ANC = 1.000/mm3 and platelet count = 50.000/mm3

- Total bilirubin = 2 x ULN

- ALT and AST = 3 x ULN

- GFR = 15ml/min as calculated by cockroft-Gault equation

8. Female patients who:

- Are older than 50 years and postmenopausal for at least 1 year before the screening visit, OR

- Are surgically sterile, OR

- If they are of childbearing potential, agree to practice 2 effective methods of contraception at the same time, from 4 weeks before starting study therapy through 90 days after the last dose of study drug, OR

- Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

- Are informed and understand the possible consequences of the teratogenic potential of thalidomide

- Male patients, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following:

- Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR

- Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

- Are informed and understand the possible consequences of the teratogenic potential of thalidomide

9. Disease free of prior malignancies for = 2 years with exception of curatively treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast if they have undergone complete resection.

Exclusion Criteria:

1. lactating females or have a positive serum pregnancy test

2. Failure to have fully recovered (i.e., = Grade 1 toxicity) from the reversible effects of prior chemotherapy

3. Previous treatment with ixazomib

4. Previous treatment with bortezomib or thalidomide within the last 3 months prior to baseline visit

5. Primary refractory to, or relapsing during, or within = 6 weeks after end of treatment with a proteasome inhibitor and/or thalidomide

6. Previous anti-cancer treatment within the last 21 days prior to baseline visit (cycle 1 / day 1), except corticosteroid therapy (40 - 160mg dexamethasone or corticosteroid dose equivalent per month)

7. Major surgery within 14 days before enrollment

8. Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib.

9. Central nervous system involvement

10. Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment

11. Evidence of current uncontrolled cardiovascular conditions

12. Systemic treatment, within 14 days before the first dose of ixazomib, with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort

13. Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive

14. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol

15. Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent

16. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing

17. Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast with are not excluded if they have undergone complete resection

18. Patient has = Grade 3 peripheral neuropathy or Grade 2 with pain on clinical examination during the screening period

19. Participation in other interventional clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ixazomib

Thalidomide

Dexamethasone


Locations

Country Name City State
Austria LKH Feldkirch, Interne E Feldkirch Vorarlberg
Austria Medizinische Universitätsklinik Graz, Klinische Abteilung für Hämatologie Graz Steiermark
Austria UK Innsbruck, Universitätsklinik für Innere Medizin, Klinische Abteilung für Hämatologie und Onkologie Innsbruck Tirol
Austria A.ö. BK Kufstein, Abteilung für Innere Medizin Kufstein Tirol
Austria Kepler Universitätsklinikum Linz, Innere Medizin 3, Zentrum für Hämatologie und medizinische Onkologie Linz
Austria KH der Elisabethinen Linz, 1. Interne Abteilung Linz Oberösterreich
Austria Ordensklinikum, KH der Barmherzigen Schwestern Linz, Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie Linz Oberösterreich
Austria Universitätsklinik der PMU Universitätsklinik für Innere Medizin III Salzburg
Austria Wilhelminenspital Vienna
Austria Klinikum Wels-Grieskirchen, IV. Interne Abteilung Wels Oberösterreich
Austria KH der Barmherzigen Brüder Wien, Innere Medizin Wien
Austria Med. Universität Wien, Universitätsklinik f. Innere Medizin I, Klin. Abt. f. Hämatologie u. Hämostaseologie Wien
Czechia Faculty Hospital Brno and Faculty of Medicine MU Brno 2nd Internal Clinic Brno
Czechia Fakultní nemocnice Ostrava Ostrava-Poruba
Germany Universitätsklinikum Leipzig - AöR Selbstständige Abteilung für Hämatologie, Internistische Onkologie und Hämostaseologie Leipzig
Germany Universitätsklinikum Tübingen, Innere Medizin II Tubingen
Germany Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II Zentrum Innere Medizin Wurzburg

Sponsors (1)

Lead Sponsor Collaborator
Arbeitsgemeinschaft medikamentoese Tumortherapie

Countries where clinical trial is conducted

Austria,  Czechia,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival (PFS) start of combination therapy to progressive disease or death due to any cause whichever occurs first, up to 4.5 years
Secondary Overall Response Rate (ORR) best and first response since start of therapy, up to 4,5 years
Secondary Overall Survival (OS) start of therapy to death, up to 4,5 years
Secondary Renal Response in a subgroup of patients with baseline GFR 15-30ml/min start of therapy to best renal response, up to 4,5 years
Secondary Determination of safety by reporting of adverse events Reporting of adverse event as a measure of safety and tolerability start of therapy to end of study therapy (appr. 2 yrs)
Secondary Assessment of prognostic values of risk factors at diagnosis incl. clinical assessment and cytogenetic abnormalities screening to end of study (appr. 2 yrs)
Secondary Correlation between altered expressions of specifically selected genes and patient´s response to the treatment regimen screening to end of study (appr. 2 yrs)
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1